Advanced Search
Current and Breaking News for Professionals, Consumers and Media

Click here to learn how to advertise on this site and for ad rates.

Disease Author: Staff Editor Last Updated: Sep 7, 2017 - 10:06:33 PM

Focusing On Bacteria's Role In Inflammatory Bowel Disease

By Staff Editor
Jul 29, 2014 - 3:45:51 PM

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust

Email this article
 Printer friendly page

( - NEW YORK, July 29, 2014 -- Early findings from a major research initiative of the Crohn's & Colitis Foundation of America (CCFA) suggest that specific bacteria play a central role in Crohn's disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD).  The evidence raises the possibility of developing new treatments to target the gut microbiome--the "ecosystem" of microbes populating the intestines--linked to the development of IBD.

Understanding the role of the gut microbes is the focus of the CCFA Microbiome Initiative.  "This research is beginning to tell us about how some 'bad' bacteria are specifically linked to IBD, IBD families, and disease flares," comments Jonathan Braun, MD, PhD, of the David Geffen School of Medicine at UCLA.  "We're still just at the beginning, but this line of research opens the possibility of manipulating the immune system and the balance of good and bad bacteria to influence the course of IBD."

The CCFA Microbiome Initiative--coordinated with another major research program, the CCFA Genetics Initiative--represents an effort to understand the interrelated microbial and genetic factors involved in Crohn's disease and UC.  Researchers working on the Microbiome Initiative recently announced initial results of a three-year study, providing valuable new insights into the differences in the gut bacteria related to IBD.

The results show significant differences in the intestinal bacteria of people with and without IBD.  What's more, those bacterial populations change when patients with Crohn's disease or UC experience a symptomatic worsening, or "flare" of their condition.  Preventing such flares is an important goal of treatment for IBD.

Highlighting the complex interplay between the microbiome and genetic factors, the study also shows that unaffected family members of patients with IBD had the "same basic profile" of gut bacteria.  Research from the CCFA Microbiome Initiative has already led to new tests to determine whether an individual has a microbial population associated with IBD.

The links between gut bacteria, risk of IBD, and IBD flares raise the possibility of monitoring the microbiome and altering it to prevent or treat IBD flares.  "For example, patients could receive medications to block specific enzymes, or dietary choices--possibly including probiotics--to stimulate a healthier microbiome," says Dr Braun.   "However," he adds, "a great deal more research will be needed to identify the most promising treatments, and design studies to evaluate their benefits for people living with IBD."

Ultimately, the combined work of the CCFA Microbiome and Genetic Initiatives may lead to the development of individualized therapy for IBD--targeted to the individual's genetic background, gut bacteria, and individual disease course.

"Researchers working on the Microbiome and Genetics Initiatives are making discoveries with real potential to lead to new treatments that can improve the lives of patients and families affected by IBD," comments Caren A. Heller, MD, MBA, the Chief Scientific Officer of the CCFA.  "We're optimistic that these lines of research will lead to a better understanding and improved clinical management of Crohn's disease and ulcerative colitis in the not-too-distant future."

Crohn's disease and ulcerative colitis are painful, medically incurable illnesses that attack the digestive system. Crohn's disease may attack anywhere along the digestive track, while ulcerative colitis inflames only the large intestine (colon). Symptoms may include abdominal pain, persistent diarrhea, rectal bleeding, fever, fatigue and weight loss. Many patients require hospitalization and surgery. These illnesses can cause severe complications, including colon cancer in patients with long-term disease. Some 1.4 million American adults and children suffer from Crohn's disease or ulcerative colitis.

About the Crohn's & Colitis Foundation of America

The Crohn's & Colitis Foundation of America (CCFA) is the largest voluntary non-profit health organization dedicated to finding cures for Inflammatory Bowel Diseases (IBD). CCFA's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults who suffer from these diseases. The Foundation works to fulfill its mission by funding research, providing educational resources for patients and their families, medical professionals, and the public, and furnishing supportive services for those afflicted with IBD. For more information, visit, call 888-694-8872, like us on Facebook, find us on LinkedIn or follow us on Twitter and Pinterest.
For ad rates, call Mike McCurdy at 877-634-9180 or email at [email protected]  We have over 7,000 journalists who are subscribers.

Top of Page

Latest Headlines

+ Shot May Help Shield Against Shingles
+ What You Should Know About Heart Valve Disease
+ Newly Discovered Gene May Protect Against Heart Disease
+ A Step Toward Sensitive and Fast Gluten Detection
+ Experimental Therapy Restores Nerve Insulation Damaged by Disease
+ When the Body Attacks the Brain
+ A New Approach to Caring for Kids with Tuberous Sclerosis Complex
+ International Genetic Study Identifies Gene Associated with Crohn’s Disease
+ Cascading Inflammation Associated with Lyme Arthritis Linked to Overactive Immune Response
+ Family Impact of Congenital Zika Syndrome Likely to Last a Lifetime

Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions